Clinical Trials

Date: 2015-12-05

Type of information: Presentation of results at a congress

phase: preclinical

Announcement: presentation of results at the 57th American Society of Hematology (ASH) Annual Meeting in Orlando

Company: ADC Therapeutics (Switzerland)

Product: ADCT-402

Action mechanism: antibody drug conjugate. ADCT-402 is an anti-CD19 PBD-conjugate, with presented data demonstrating potent and specific in vitro and in vivo anti-tumor activity against CD19-positive hematological tumors as well as excellent tolerability.

Disease: hematological cancers

Therapeutic area: Cancer - Oncology

Country:

Trial details:

Latest news:

• • On December 5, 2015, ADC Therapeutics, an  oncology drug development company, presented pre-clinical results for  ADCT-402, its novel Antibody Drug Conjugates (ADCs) in hematological tumours at the 57th American Society of Hematology (ASH) Annual Meeting, December 5-8, in Orlando, Florida.  ADCT announced that it has received IND clearance from the FDA to begin two Phase I clinical trials with ADCT-402 in hematological tumors. The pre-clinical studies referenced above were conducted jointly by ADC Therapeutics, Spirogen (a division of AstraZeneca) and University College London, London.

Is general: Yes